

Hideyuki Saya, M.D., Ph.D.

Keio University



- 1981 M.D., Kobe University, School of Medicine, Kobe, Japan
- 1987 Ph.D., Kobe University, Graduate School of Medical Science, Kobe, Japan
- 1987-1988 Postdoctoral Fellow, University of California, San Francisco, CA, USA
- 1988-1994 Assistant Professor, The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA
- 1994-2006 Professor, Kumamoto University School of Medicine, Kumamoto, Japan
- 2007-present Professor, Keio University School of Medicine, Tokyo, Japan

Specialty & Research Field of Interest

Cancer Stem Cell, Cell Differentiation

Selected Publications

1. Shimizu T, et al.: IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress. **Cancer Res** 2014 (in press)
2. Nobusue H, et al.: Regulation of MKL1 via actin cytoskeleton dynamics drives adipocyte differentiation. **Nat Commun** 5: 3368, 2014
3. Yoshikawa M, et al.: xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. **Cancer Res** 73: 1855-1866, 2013
4. Osuka S, et al.: IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. **Stem Cells** 31: 627-640, 2013
5. Yae T, et al.: Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. **Nat Commun** 3: 883, 2012
6. Tamada M, et al.: Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. **Cancer Res** 72: 1438-1448, 2012
7. Oikawa T, et al.: Acquired expression of NFATc1 downregulates E-cadherin and promotes cancer cell invasion. **Cancer Res** 73: 5100-5109, 2013
8. Ishimoto T, et al.: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc- and thereby promotes tumor growth. **Cancer Cell** 19: 387-400, 2011